No article text was recorded for this version.
anti-vector immunity
Version 1 of 132 papers47 conceptsfrozen 2026-10-04
Papers in this version
- Blog: Vesicular stomatitis virus-based vaccine targeting plasmodium blood-stage antigens elicits immune response and protects against malaria with protein booster strategy
- Blog: HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial
- Blog: Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial
- Blog: Immunogenicity and safety of quadrivalent influenza vaccine among young and older adults in Tianjin, China: implication of immunosenescence as a risk factor
- Blog: Combination therapy with oncolytic viruses and immune checkpoint inhibitors in head and neck squamous cell carcinomas: an approach of complementary advantages
- Blog: Engineered oncolytic virus expressing B7H3-targeting BiTE enhances antitumor T-cell immune response
- Blog: Oncolytic Activity of a Chimeric Influenza A Virus Carrying a Human CTLA4 Antibody in Hepatocellular Carcinoma
- Blog: Heterologous arenavirus vector prime-boost overrules self-tolerance for efficient tumor-specific CD8 T cell attack
- Blog: In vivo applications and toxicities of AAV-based gene therapies in rare diseases
- Blog: DNA and recombinant adenovirus serotype 35 and 5 preventive HIV-1 vaccines with Env A inserts elicit cross-clade binding and V1V2 antibodies
- Blog: Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer
- Blog: Adenovirus Vaccine Containing Truncated SARS-CoV-2 Spike Protein S1 Subunit Leads to a Specific Immune Response in Mice
- Blog: Engineered oncolytic virus coated with anti-PD-1 and alendronate for ameliorating intratumoral T cell hypofunction
- Blog: Evaluation of <i>Leishmania</i> homolog of activated C kinase (LACK) of <i>Leishmania donovani</i> in comparison to glycoprotein 63 as a vaccine candidate against visceral leishmaniasis
- Blog: Immunization with Adenoviral Vectors Carrying Recombinant IL-12 and E7 Enhanced the Antitumor Immunity against Human Papillomavirus 16-associated Tumor
- Blog: Immunization with an adenovirus-vectored TB vaccine containing Ag85A-Mtb32 effectively alleviates allergic asthma
- Blog: Determining vaccine responders in the presence of baseline immunity using single-cell assays and paired control samples
- Blog: Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa
- Blog: Live attenuated varicella-zoster virus vaccine does not induce HIV target cell activation
- Blog: In Vivo Delivery Systems for Therapeutic Genome Editing
- Blog: The PARP inhibitor talazoparib synergizes with reovirus to induce cancer killing and tumour control in vivo in mouse models
- Blog: Resistance mutations that distinguish HIV-1 envelopes with discordant VRC01 phenotypes from multi-lineage infections in the HVTN703/HPTN081 trial: implications for cross-resistance
- Blog: P19-08. Immunisation with recombinant HLA class I and II, HIV-1gp140 and SIVp27 antigens elicits protection against SHIV-SF162P4 infection in rhesus macaques
- Blog: Efficacy and adverse reaction management of oncolytic viral intervention combined with chemotherapy in patients with liver metastasis of gastrointestinal malignancy
- Blog: Inhibitory effects of human lactoferrin on U14 cervical carcinoma through upregulation of the immune response
- Blog: Combination therapy with oncolytic virus and T cells or mRNA vaccine amplifies antitumor effects
- Blog: RCAd-LTH-shPD-L1, a double-gene recombinant oncolytic adenovirus with enhanced antitumor immunity, increases lymphocyte infiltration and reshapes the tumor microenvironment
- Blog: Producing high-quantity and high-quality recombinant adeno-associated virus by low-cis triple transfection
- Blog: Bacteriophage T4 Vaccine Platform for Next-Generation Influenza Vaccine Development
- Blog: An inactivated recombinant rabies virus displaying the Zika virus prM-E induces protective immunity against both pathogens
- Blog: 679 Characterization of tumor specific CD8+ T cell responses in patients with recurrent/metastatic HPV16-positive head and neck cancer receiving HB-200 monotherapy as second or later line treatment in a phase 1 study
- Blog: In Vivo Delivery of Adenoviral Vector Containing Interleukin-17 Receptor A Reduces Cardiac Remodeling and Improves Myocardial Function in Viral Myocarditis Leading to Dilated Cardiomyopathy
History & citation
Current · Permanent link
- Overcoming Anti-Vector Immunity in Viral Delivery Systems merged into this direction (81% overlap)
Cite this direction
Latest version (a living page):
@misc{lacuna_anti_vector_immunity_88c039ce,
title = {anti-vector immunity},
author = {{Lacuna}},
howpublished = {Lacuna research direction},
year = {2026},
url = {https://lacuna.tiptreesystems.com/direction/anti-vector-immunity/rdr_88c039ced4574c67899d35d636cfbc91},
note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-19},
}This exact version (version 1, frozen text):
@misc{lacuna_anti_vector_immunity_88c039ce_v1,
title = {anti-vector immunity},
author = {{Lacuna}},
howpublished = {Lacuna research direction},
year = {2026},
url = {https://lacuna.tiptreesystems.com/direction/anti-vector-immunity/rdr_88c039ced4574c67899d35d636cfbc91/v/1},
note = {Version 1, frozen 2026-10-04. Accessed 2026-11-19},
}